PENDING CLAIMS

Docket No.: 65507(41925)

Claims 1-18. (Canceled)

Claim 19. (Previously presented) A compound of formula (I)

$$R^{5} \xrightarrow{\text{Y}} A - Q \xrightarrow{(CH_{2})_{n}} N \xrightarrow{\text{R}^{2}} R^{1} \xrightarrow{\text{Q}} O$$

$$(CH_{2})_{m} N \xrightarrow{\text{Y}} X \xrightarrow{\text{Q}} O$$

$$(I) \qquad R^{3}$$

wherein

A is $-OCH_2$ -;

Q is CR⁴;

X is CR⁷ or N;

Y is CH;

n is 2;

m is 2;

 R^1 is H;

R² is H or F;

 R^3 is H, an ethyl, a propyl, a C_3 - C_6 cycloalkyl group, a phenyl, or a pyridyl group; all of which may be substituted with one, two, three, or more fluorine atoms or amino groups;

 R^4 is hydroxy, a group of formula $OPO_3R^9_2$, OSO_3R^{10} , $OCH_2OPO_3H_2$, $OCOCH_2CH_2COOH$ or an ester of a naturally occurring amino acid, wherein the groups R^9 independently of each other are H, alkyl, cycloalkyl, aryl or aralkyl and wherein R^{10} is H, alkyl, cycloalkyl, aryl or aralkyl;

 R^5 is

Application No. 10/583,419 Amendment dated August 25, 2011

Docket No.: 65507(41925)

R⁷ is H or a methoxy group, or

 R^3 and R^7 together form a bridge of the formula $-O\text{-}CH_2\text{-}N(Me)\text{-}$ or $-O\text{-}CH_2\text{-}CH(Me)\text{-}$; and R^8 is $-CH_2NHCOMe$;

or a pharmacologically acceptable salt or formulation thereof.

Claim 20-22. (Canceled)

Claim 23. (Previously presented) A compound according to claim 19, wherein R³ is a cyclopropyl group.

Claim 24. (Previously presented) A compound of claim 19, wherein R⁷ and R³ together form a bridge of the formula –O-CH₂-N(Me)- or -O-CH₂-CH(Me)-, wherein the preferred stereochemistry at the chiral center is the one giving the (S) configuration in the final compound.

Claim 25. (Canceled)

Claim 26. (Previously presented) A compound of claim 19, wherein X is N or CH.

Claim 27. (Previously presented) A compound of claim 19, wherein R⁴ is hydroxy or a group of formula OSO₃H, OPO₃H₂, OCH₂OPO₃H₂, OCOCH₂CH₂COOH or an ester of a naturally occurring amino acid.

Claim 28. (Canceled).

Claim 29. (Previously presented) A compound of claim 19, wherein R⁵ has the following structure:

Application No. 10/583,419 Amendment dated August 25, 2011

Docket No.: 65507(41925)

Claim 30-32. (Canceled)

Claim 33. (Previously presented) A mono, di or tri sodium salt of a compound of formula (I) according to claim 19.

Claim 34. (Previously presented) A compound of claim 33 wherein R^4 is OPO_3H_2 or OSO_3H or mixtures thereof.

Claim 35. (Previously presented) A pharmaceutical composition comprising a compound of claim 19.

Claim 36. (Previously presented) The pharmaceutical composition of claim 35 further comprising one or more optionally carriers and/or adjuvants and/or diluents.

Claim 37. (Canceled)

Claim 38. (Previously presented) A method for treating a subject suffering from or susceptible to a bacterial infection, comprising administering to the subject a compound of claim 19.